RCM
BIOTW

Radcliffe Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Radcliffe Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-202,950
Closed -$2.05M – 858
2022
Q4 		$2.05M Hold
202,950
– – 0.06% 465
2022
Q3 		$2.01M Hold
202,950
– – 0.05% 643
2022
Q2 		$2.01M Hold
202,950
– – 0.05% 656
2022
Q1 		$2M Hold
202,950
– – 0.05% 641
2021
Q4 		$2M Hold
202,950
– – 0.05% 555
2021
Q3 		$1.98M Hold
202,950
– – 0.06% 468
2021
Q2 		$1.96M Buy
+202,950
New +$141K 0.06% 506

Radcliffe Capital Management's BIOTW Position: Q1 2023 in Review

Radcliffe Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 202,950 shares — an estimated $2.05M sold.

Radcliffe Capital Management first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $2.05M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

  • Radcliffe Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 202,950 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $2.05M.
  • Radcliffe Capital Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
  • Radcliffe Capital Management's Biotech Acquisition Company Warrant position peaked at $2.05M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.